Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2024 07:00 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces $30 Million Private Placement Financing

Relay Therapeutics Announces $30 Million Private Placement Financing
January 02, 2024 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
November 07, 2023 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference

Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference
November 02, 2023 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights

Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
October 26, 2023 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023

Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
October 12, 2023 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors

Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
September 18, 2023 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
August 08, 2023 16:02 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights

Initiated dose expansion cohort for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Updated RLY-2608 600mg BID + fulvestrant data: interim clinical...
August 01, 2023 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023

CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
May 25, 2023 17:01 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008

CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...